ATE412905T1 - Diagnoseverfahren für lebersteatose unter verwendung biochemischer marker - Google Patents

Diagnoseverfahren für lebersteatose unter verwendung biochemischer marker

Info

Publication number
ATE412905T1
ATE412905T1 AT06710408T AT06710408T ATE412905T1 AT E412905 T1 ATE412905 T1 AT E412905T1 AT 06710408 T AT06710408 T AT 06710408T AT 06710408 T AT06710408 T AT 06710408T AT E412905 T1 ATE412905 T1 AT E412905T1
Authority
AT
Austria
Prior art keywords
diagnostic methods
biochemical markers
liver steatosis
patient
drawn
Prior art date
Application number
AT06710408T
Other languages
English (en)
Inventor
Thierry Poynard
Original Assignee
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of ATE412905T1 publication Critical patent/ATE412905T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Hematology (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Microbiology (AREA)
  • Software Systems (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
AT06710408T 2005-02-03 2006-02-03 Diagnoseverfahren für lebersteatose unter verwendung biochemischer marker ATE412905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/050,396 US7860656B2 (en) 2005-02-03 2005-02-03 Diagnosis method of hepatic steatosis using biochemical markers

Publications (1)

Publication Number Publication Date
ATE412905T1 true ATE412905T1 (de) 2008-11-15

Family

ID=36097137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06710408T ATE412905T1 (de) 2005-02-03 2006-02-03 Diagnoseverfahren für lebersteatose unter verwendung biochemischer marker

Country Status (13)

Country Link
US (2) US7860656B2 (de)
EP (1) EP1856536B1 (de)
JP (1) JP2008529030A (de)
CN (1) CN101175998A (de)
AT (1) ATE412905T1 (de)
BR (1) BRPI0606840A2 (de)
CA (1) CA2596682A1 (de)
DE (1) DE602006003414D1 (de)
IL (1) IL185021A0 (de)
MA (1) MA29282B1 (de)
MX (1) MX2007009427A (de)
RU (1) RU2403576C2 (de)
WO (1) WO2006082522A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178294B2 (en) * 2002-06-14 2012-05-15 Cedars-Sinai Medical Center Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
US9012162B2 (en) 2006-09-08 2015-04-21 The Chancellor, Masters And Scholars Of The University Of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US20100130600A1 (en) * 2007-03-30 2010-05-27 Cedars-Sinai Medical Center Lipoprotein lipase and its effect on statin treatments
JP2009114092A (ja) * 2007-11-02 2009-05-28 Mcbi:Kk 慢性肝炎、肝硬変、肝がんの分別診断のための新規バイオマーカーおよび該バイオマーカーを用いた慢性肝炎、肝硬変、肝がんの分別診断方法
EP2546649B1 (de) 2007-11-02 2015-02-25 Metabolon Inc. Biomarker für Fettleberkrankheit und Verfahren zur Verwendung davon
WO2009069776A1 (ja) * 2007-11-30 2009-06-04 National University Corporation Hokkaido University 糖鎖分析による肝疾患の診断方法
EP2286236B1 (de) * 2008-05-28 2016-04-20 Basf Se Verfahren zur beurteilung einer lebertoxizität
EP2157431A1 (de) 2008-08-11 2010-02-24 One Way Liver Genomics, S.L. Verfahren zur NASH-Diagnose unter Verwendung von Stoffwechselprofilen
CA2735582A1 (en) * 2008-08-28 2010-03-04 Salutria Pharmaceuticals, Llc Screening method for identifying patients at risk of adverse hepatologic events
US20120088245A1 (en) * 2008-10-31 2012-04-12 Cedars-Sinai Medical Center Methods of diagnosing insulin resistance and sensitivity
ES2621838T3 (es) 2008-11-18 2017-07-05 Universite D'angers Método in vitro no invasivo para la cuantificación de lesiones hepáticas
US9585613B2 (en) * 2009-02-26 2017-03-07 Universite D'angers Diagnosis of liver fibrosis and cirrhosis
ES2527455T3 (es) * 2009-05-14 2015-01-23 The Chancellor, Masters And Scholars Of The University Of Oxford Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes
EP2309276A1 (de) 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Verfahren zur Diagnose von nichtalkoholischer Steatohepatitis basierend auf einem metabolomischen Profil
EP2327988A1 (de) 2009-11-28 2011-06-01 Assistance Publique Hôpitaux De Paris Verfahren zur Diagnose von fibrotischen Erkrankungen
EP2567241B1 (de) * 2010-05-03 2015-11-04 The Cleveland Clinic Foundation Erkennung und überwachung von nicht alkoholbedingter fettleber
EP2418285A1 (de) * 2010-08-09 2012-02-15 Universiteit Maastricht Verfahren zur Diagnose von Fettlebererkrankungen, insbesondere von nicht alkoholischer Steato-Hepatitis
FR2971256B1 (fr) 2011-02-09 2024-09-27 Bio Rad Pasteur Combinaison de biomarqueurs pour la detection et l'evaluation d'une fibrose hepatique
RU2476154C1 (ru) * 2011-08-12 2013-02-27 Государственное образовательное учреждение высшего профессионального образования "Смоленская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации Способ диагностики алкогольной болезни печени
US20140236621A1 (en) * 2011-09-26 2014-08-21 Universite Pierre Et Marie Curie (Paris 6) Method for determining a predictive function for discriminating patients according to their disease activity status
EP2600266A1 (de) 2011-12-02 2013-06-05 Biopredictive Verfahren zur Diagnose von fibrotischen Erkrankungen
EP2810079A4 (de) * 2012-01-31 2015-08-05 Teknologian Tutkimuskeskus Vtt Oy Verfahren zur bestimmung der leberfettmenge und verfahren zur diagnose von nafld
WO2014049131A1 (en) * 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis
BR112015008621A2 (pt) * 2012-10-17 2018-08-28 Enterome Métodos e kit de diagnóstico e/ou prognóstico in vitro microconjunto de ácidos nucleicos.
RU2545990C2 (ru) * 2013-07-16 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ дифференциальной диагностики стеатоза печени и стеатогепатита
RU2557927C1 (ru) * 2014-06-05 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТГМУ Минздрава России) Способ диагностики фиброза печени при хроническом вирусном гепатите с
FR3023003B1 (fr) 2014-06-27 2016-07-15 Bio-Rad Innovations Combinaison synergique de biomarqueurs pour la detection et l'evaluation d'une fibrose hepatique
ES2741357T3 (es) 2015-03-17 2020-02-10 Servicio Andaluz De Salud Métodos de análisis óptico computarizado de imágenes de MR (resonancia magnética) para cuantificar o determinar lesiones hepáticas
CN115236166A (zh) 2016-05-29 2022-10-25 深圳市绘云生物科技有限公司 肝病相关生物标志物和其使用方法
CN106127256A (zh) * 2016-06-30 2016-11-16 张云超 一种肝纤维化检测方法及装置
EP3267199A1 (de) 2016-07-06 2018-01-10 One Way Liver S.L. Diagnostische methoden basierend auf lipidprofilen
EP3296744A1 (de) * 2016-09-16 2018-03-21 Biopredictive Verfahren zur diagnose nichtalkoholischer fettlebererkrankungen
CN106771201A (zh) * 2016-12-05 2017-05-31 江西惠肽生物科技有限公司 用于肝纤维化诊断试剂盒及其检测方法
WO2018156717A1 (en) 2017-02-24 2018-08-30 The Cleveland Clinic Foundation Method and apparatus for time-differential deployment of an endovascular device within a body lumen
EP3373012A1 (de) 2017-03-07 2018-09-12 Biopredictive Verfahren zur diagnose von arzneimittelinduzierter leberverletzung
ES2902226T3 (es) 2017-07-19 2022-03-25 Bio Rad Europe Gmbh Combinaciones de biomarcadores para evaluar la esteatohepatitis no alcohólica y/o el estatus de la fibrosis hepática
CN111279195B (zh) 2017-10-16 2024-01-23 生物预测公司 原发性肝癌的预后和随访方法
EP3470843A1 (de) 2017-10-16 2019-04-17 Biopredictive Verfahren zur prognose von primärem leberkrebs
CN108565024B (zh) * 2018-03-19 2020-05-05 首都医科大学附属北京地坛医院 一种确定单发的hbv相关原发性小肝癌术后1年内复发风险的系统
CN108417267B (zh) * 2018-03-19 2020-05-05 首都医科大学附属北京地坛医院 一种确定肝硬化肝肾综合征患者短期预后的系统
CN108932976A (zh) * 2018-06-11 2018-12-04 西安医学院 一种非酒精性脂肪性肝病无创性诊断程序
RU2684201C1 (ru) * 2018-07-05 2019-04-04 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ скрининговой диагностики жировой дегенерации печени при абдоминальном ожирении
EP3599615A1 (de) * 2018-07-27 2020-01-29 Biopredictive Verfahren zur diagnose von lebersteatose
EP3836929A1 (de) * 2018-08-14 2021-06-23 Camp4 Therapeutics Corporation Verfahren zur behandlung von lebererkrankungen
US20210005327A1 (en) * 2019-07-05 2021-01-07 Molecular You Corporation Method and system for personalized, molecular based health management and digital consultation and treatment
CN111583993A (zh) * 2020-05-29 2020-08-25 杭州广科安德生物科技有限公司 构建体外检测癌症的数学模型的方法及其应用
RU2753455C1 (ru) * 2020-12-11 2021-08-16 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Способ дифференциальной диагностики стеатоза печени и неалкогольного стеатогепатита у мужчин
RU2755974C1 (ru) * 2021-03-11 2021-09-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ диагностики неалкогольного стеатоза печени
RU2763257C1 (ru) * 2021-05-14 2021-12-28 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ диагностики стадии фиброза печени при хронических заболеваниях печени у детей
JP2025500409A (ja) 2021-12-22 2025-01-09 キャンプ４ セラピューティクス コーポレイション 調節ｒｎａを標的とするアンチセンスオリゴヌクレオチドを用いた遺伝子転写の調節方法
EP4555924A1 (de) 2023-11-15 2025-05-21 Assistance Publique - Hôpitaux de Paris Verfahren zur bestimmung der gebrechlichkeit unter verwendung von anästhesiedaten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2183326C2 (ru) * 2000-03-03 2002-06-10 Харламова Флора Семеновна Способ диагностики фиброза печени при хроническом гепатите у детей
US6631330B1 (en) * 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
RU2261441C2 (ru) * 2003-10-06 2005-09-27 Ягода Александр Валентинович Способ неинвазивной диагностики степени выраженности фиброза печени у больных хроническим вирусным гепатитом
US7856319B2 (en) * 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers

Also Published As

Publication number Publication date
US20090111132A1 (en) 2009-04-30
DE602006003414D1 (de) 2008-12-11
MX2007009427A (es) 2008-03-06
CA2596682A1 (en) 2006-08-10
WO2006082522A1 (en) 2006-08-10
BRPI0606840A2 (pt) 2010-03-09
RU2007132921A (ru) 2009-03-10
US20060173629A1 (en) 2006-08-03
EP1856536B1 (de) 2008-10-29
EP1856536A1 (de) 2007-11-21
IL185021A0 (en) 2007-12-03
MA29282B1 (fr) 2008-02-01
JP2008529030A (ja) 2008-07-31
US7860656B2 (en) 2010-12-28
CN101175998A (zh) 2008-05-07
RU2403576C2 (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
ATE412905T1 (de) Diagnoseverfahren für lebersteatose unter verwendung biochemischer marker
ATE319093T1 (de) Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen
WO2006103570A8 (en) Diagnosis method of alcoholic or non-alcoholic steato-hepatitis using biochemical markers
DK2073008T3 (da) Forbedrede immunoassayfremgangsmåder
ATE442590T1 (de) Verfahren zur schnelldiagnose von zielen in menschlichen kírperflüssigkeiten
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
WO2008021290A8 (en) Organ-specific proteins and methods of their use
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
DE60239470D1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
EP2138848A4 (de) Verfahren zur diagnose und/oder prognose von blasenkrebs
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
NZ592819A (en) Thyroid analyte detection and measurement
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
TW200502400A (en) Nucleic acid detection
DE60330505D1 (de) Verfahren zur erkennung eines kolonkrebsmarkers
WO2009014342A3 (en) Markers and kit for diagnosis of alzheimer's disease
DE602004030036D1 (de) Multiplexanalyse von Nukleinsäuren zur Bestimmung von Genotypen des humanen Papillomavirus
WO2012033382A3 (ko) 신규한 ｒｎａ 결합 단백질 및 이를 이용한 무표지 마이크로 ｒｎａ 검출방법
EP1767652A4 (de) Genmarker und dessen verwendung
ATE472102T1 (de) Verfahren zur vorhersage von anomalien des lipidmetabolismus
WO2022241292A3 (en) Use of markers in the diagnosis and treatment of parkinson's disease
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
ATE477488T1 (de) Verfahren zur bestimmung einer dna- bindungsprotein-menge

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties